An improved extraction procedure for an HPLC method for Cyclosporin A in whole blood and plasma SMA G U IRE. F K Y N E and D U a CON A ILL From the Biochemistry Department. Mater Misericordiae Hospital. Dublin. Ireland SUMMARY. Cyclosporin A (CyA) was assayed by high performance liquid chromatography (HPLC) following extraction of the whole blood or plasma with diethyl ether and chromatography on a Sep-Pak Silica cartridge. Using carefully chosen volumes and ratios of ethyl acetate and hexane in the eluting sequences on the Sep-Pak , the major interferent present in normal blood and serum was eliminated.
Cyclosporin A (CyA) is an undecapeptide of fungal origin which has proved to be an effective immunosuppressant in the prevention of graft rejection. ' Side-effects of CyA therapy include nephrotoxicity and hepatotoxicity' and increased susceptibility to opportunistic infection.:' Differentiation between allograft rejection and cyclosporin-induced nephrotoxicity is difficult." Thus. the levels of CyA in plasma or whole blood of patients must be both biologically effective and non-toxic. necessitating the careful monitoring of CyA levels. Of the two techniques currently available. radioimmunoassay (RIA) is the more widely used but suffers from lack of specificity as the antibody used cross-reacts with some of the metabolites of CyA. 5 Assay with high performance liquid chromatography (HPLC) is more tedious than RIA. yet is more specific in that only the parent compound CyA is measured. Recently. it was reported by Oosthuizen, Jacobs and Myburgh" that an interfering compound. designated X. elutes very ncar to the CyA peak. In their system CyA eluted at 10·5 min and X at 10·3 min. This latter compound was present in two out of four control blood samples. This group described an improved extraction procedure which differed from that of Carruthers et al. • 7 Allwood and Lawrance" and other workers. Since X was thought to be a protein also extracted in their new procedure. they introduced the step of hydrolysing it by incubating the plasma with proteinase K for 3 h at 37°C. We also encountered an interferent which may 
Standard solution of ()A
A stock solution of CyA was prepared by dissolving 20 mg in UK) mL of methanol. A dilution of Il)() !!L of this up to 5 mL methanol yielded a suitable working solution.
Internal standard solution of CyD
A stock solution of CyD was prepared by dissolving 20 mg of CyD in UK) mL methanol. A dilution of 8lK) !!L up to 20 mL yielded a suitable working solution.
Maguire. Kyne and UaConail/ Preparation of standards in plasma 50, 100 and 200 I!L of working CyA standard was added to separate clean dry glass tubes. This corresponded to 2UO, 400 and ROO ng of CyA. The methanol was evaporated to dryness under nitrogen. Then 1 mL of pooled pretransplant plasma was added to each tube and the tubes were vortex-mixed. The internal standard was then added to each tube in a volume of 100 tJ,L of working solution using a Hamilton syringe. All standards were extracted in the same way as patient samples. Plastic utensils of any kind were avoided in the preparation of standards and in the extraction procedure to avoid extraneous peaks.
FINAl. EXTRACTION PROCEI1URF.
In a clean glass tube 3·5 mL of diethyl ether were added to 1 mL of plasma or whole blood containing the internal standard. The tube was vortexed for 5 min and then centrifuged at 2000g for 5 min. The supernatant was removed to a clean glass tube and the extraction was repeated. The 7 mL of ether was dried under nitrogen in a 37°C water bath and the residue was dissolved in 1 mL of a 20:RO ethyl acetate: hexane solvent mixture. A Silica Sep-Pak was pre-washed with IS mL of the 2U:&0 ethyl acetate:hexane mixture and the sample was applied to the Sep-Pak. The cartridge was washed successively with three different ethyl acetate: hexane mixtures, 15 mL of 20:80, 40 mL of 40:60, and 50 mL of 45:55; and the eluate was discarded on each occasion. The cartridge was then washed with )() mL of ethyl acetate and the eluate was collected in a clean glass tube. The ethyl acetate was evaporated to dryness under nitrogen and the residue was redissolved in Il)() tJ,L of mobile phase. Of this solution, 70 tJ,L was then injected onto the column. Extractions of saline were regularly performed to ensure the purity of the solvents used.
CHROMATOGRAPHIC CONIlITIONS
For high performance liquid chromatography a Waters Associates system (Milford, MA. USA) was used. It consisted of a Model 501 pump, a WISP 7108 Automatic Injection System. and a Model 440 absorbance detector with an extended wavelength module. Peaks were integrated with a 740 Data Module System. Separations were carried out on a 30 cm ubondapak CIK reversed phase column, with a Guard-Pak pre-column module inserted before the column. The pre-column inserts were of the Resolve CN type which did not retain the cyclosporins. A column heater (Jones Chromatography Ltd. South Wales, UK) of the 7930 series was used to maintain column temperature at n°e. This was insulated on the outside with styrofoam wrapped in aluminium. The mobile phase was methanol:water 77:23 by volume, and the flow rate used depended on the age of the column, varying between H) and 1·:\ mUmin. An attenuation of O·(l2 AUFS at 214 nm was used to monitor the column effluent.
Chromatography of C.vA 2 ug of CyA in 0·2 mL methanol were added to I mL saline and this was taken through the extraction procedure down to the end of the first ethyl acetate:hexane wash. Various eluting solvents were then used in the subsequent steps and each mL of each eluate was collected separately, dried under nitrogen. reconstituted in mobile phase and then injected onto the column.
Resulls and discussion
In setting up an assay for CyA in human plasma the extraction method used was a modification of that of Varghese et al. ' This involved the use of Sep-Pak Silica cartridges unlike the method of Allwood and Lawrance" in which the reversed phase CIK Sep-Pak cartridge was used. With the Silica Sep-Pak , low polarity compounds were eliminated in the extraction procedure by washing with 15 mL of 211:80 ethyl acetate:hexane. To determine what was eluted from the cartridge by this solvent, the eluate from several control plasma samples were dried down under nitrogen, reconstituted in mobile phase and then injected onto the column. Six middle-eluting compounds were usually detected with retention times relative to CyD of 0·8, 11·82, 0·88. 11·94, 11·98 and 1·()4 compared with a value of 11·8 for CyA. No loss of CyA or CyD occurred in this step. Further elution with this solvent yielded a flat baseline in the area of the cyclosporins.
When 10 mL of ethyl acetate were then used to elute CyA off the column some interfering compounds were present. in particular a compound that eluted at 13·9 min yielding a relative retention time of 11·75 (Fig. la, c) . It behaved very similarly to the compound X described by Oosthuizen et ul.e. (retention times in their case 10·3 min for X. 11I·5 min for CyA and 13·9 min for CyD). and for convenience here was termed compound X. or X for short. It cannot be assumed to be the same X as described previously. This compound did not disappear from samples even after storage at -20°C for 6 months. It was present in approx-(yA in whole blood and plasma imately half the normal controls and half of the patients tested. Once detected in a particular patient's plasma specimen. it was consistently present for weeks or months afterwards. Since all specimens were collected in plastic containers. it did not seem likely that X arose from this source. but further evidence in this laboratory suggests that some specimen containers may indeed produce such interferents. However, this aspect of the problem is not addressed here.
Whereas Oosthuizen et al" used a column temperature of 56°C. 72°C was preferred in the present assay as 7(f-80°C has been recommended for octadecyl-bonded columns" due to the inability of an octadecyl-bonded phase to resolve completely several conformers of cyclosporin A. The period of use of the CIK column was found to playa critical role in the separation of CyA and X on the CIK column. The length of time that the column is maintained at 72°C is the critical factor. rather than the number of injections made. On a new column at a flow rate of 1·0 mUmin, CyA and X elute as two distinct peaks but are poorly separated (Fig. 2b) . After a few weeks' column use however, X merges increasingly with CyA. and integration of the CyA peak is rendered difficult. In normal controls when X coeluted with CyA. the apparent CyA levels varied from 50 to WOO ug/L. With prolonged use X elutes after CyA and an extreme example is shown in Fig. 2A where X may actually begin to merge with CyD. For all these reasons it becomes vital to eliminate X in the extraction procedure since if it is not extracted its elution time is too variable in and around CyA and CyD. It was then decided to examine the extraction in an effort to separate CyA from X at this stage.
The extraction procedure described extracts none of compound X. It was arrrived at by looking at different ratios and volumes of ethyl acetate and hexane to see how CyA and X could best be separated during the extraction. Where the Sep-Pak cartridge is washed with 40 mL of 4():60 ethyl acetate.hexane, 10 mL of 4():60 ethyl acetate.hexane was first tried. followed by 10 mL of ethyl acetate. Each mL of the 20 mL of eluate was separately collected in clean glass tubes, dried under nitrogen. reconstituted in mobile phase and then injected onto the column. Compound X was prepared separately for chromatography. For each study. three 1 mL aliquots of control plasma, found to contain high levels of X, were taken as far as the ether extraction. The ether from the three samples was pooled and evaporated in one tube and the extraction was continued to the end of the first ethyl acetate:hexane wash. Various solvents were then used in the subsequent eluting steps and each mL of each eluate was collected separately. dried under nitrogen, reconstituted in mobile phase and then injected onto the column. The relative amounts of CyA and X in each mL of the 20 mL is shown in Fig. 3a . It can be seen that J() mL of 40:60 ethyl acetate.hexane elutes off IO'X. of X but CyA remains on the cartridge. On switching to ethyl acetate both compounds clute together in a similar pattern. Figure 3b shows that the use of J() mL of 60:40 ethyl acetate.hexane elutes 73'Yo of X and IS'X. of CyA off the Sep-Pak cartridge. 10 mL of ethyl acetate then elutes X5% of CyA and 23% of X.
Various combinations of these and other solvents were then tried in order to obtain a protocol that would completely eliminate X and yet yield good recovery of CyA. This proved difficult since the two compounds have very similar polarities. In Fig. 3b , when the first 5 mL of ethyl acetate was discarded, X was not found in the remaining 5 mL when collected, but recovery of CyA was unacceptably low. If 20 ml, of 60:40 ethyl acetate.hexane was used instead of 10 mL in the same Fig. 3h , a further 20% loss of CyA was incurred with some X still remaining on the cartridge. Using larger volumes of 40:60 ethyl actetate:hexane such as 40 ml., X was largely eluted off the cartridge yet CyA remained. Switching to a more polar solvent after this step, 45:55 ethyl acetate.hexanc, X was eluted completely off the cartridge in a further volume of 50 mL. The loss of CyA over the combined 90 mL of the two solvents was only 20%. Figure The final extraction procedure as outlined above is a compromise between separation of CyA from interfcrents on the one hand and good recovery of CyA on the other. Compound X is eliminated from plasma and whole blood and yet the overall absolute recovery for Cy A is 45±2 (mean=±SD). This figure was obtained by comparing peak areas generated hy extracted and unextracted standards in 10 assays. Most of the loss is due not to the solvents used but to the amount of CyA remaining on the Sep-Pak cartridge, which can he eluted off with CyA in whole blood and plasma 165 a more polar solvent such as methanol. For convenience, this proportion of CyA was not considered in the recovery percentages until now, and all previous figures relate to CyA as a percentage of CyA eluted by all solvents up to and including ethyl acetate. The use of 10 mL of acetonitrile instead of 10 rnl, of ethyl acetate in the final wash yielded no increase in absolute overall recovery.
In the plasma assay finally used, the sensitivity limit (signal equal to twice the baseline noise) was }(~20 f.lglL. The within-run precision showed a CV of 2% at a level of 1000 ug/L, 5% at a level of 310 Jl.glL and 10% at a level of 120 ug/l., with n= 10 in all cases. The betweenrun precision showed a CV of 6% at a level of 310 Jl.glL (n=25) and analytical recovery of CyA added to plasma at a concentration of 360 ug/L averaged 99% in three different assays. The assay was linear over the range tested (~IOOO f.lglL. Interference from exogenous substances was checked but no peaks coeluted with CyA in all the pooled plasma samples used for making up standards, in plasma samples from patients not receiving CyA, or in plasma samples deliberately supplemented with various drugs (sedatives, hypnotics, antibiotics, antiarrhythmic agents, analgesics, antidepressants, anti-hypertensive agents and corticosteroids).
The HPLC method described here is suitable for the measurement of CyA in plasma. serum and whole blood. The preparative phase is time-consuming but perhaps less so than some other methods in the literature. Because compound X is eliminated in the extraction procedure. there is no need to include a buffer salt in the mobile phase as is necessary in the method of Kabra, Wall and Blanckaert, III or in the reconstitution solvent as is necessary in the method of Carruthers et al. ' Late peaks which prolong the chromatography time are also absent. With the absence of interfering peaks, the scope is provided to increase either the flow rate or the proportion of methanol in the mobile phase, yielding quick elution times for the cyclosporins. For routine assays we use a mobile phase which consists of methanol:water 80:20, and with a flow-rate of 1·2 mUmin CyA elutes at 9·6 min and CyD at 1l·2 min.
